Atropine

Evidence Level: L4

Predicted Indications: 2

Atropine

Pharmacist Assessment Report

Atropine: From Anticholinergic Use (Original Indication Not Specified in Licence Data) to Migraine Disorder

One-Sentence Summary

Atropine is a non-selective muscarinic antagonist marketed in India in injectable, oral and eye-drop products, though the licence records compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for migraine disorder, but there are 0 clinical trials and only indirect, mostly preclinical literature, so this is a research question rather than a supported use.

Quick Overview

Item	Content
Original Indication	Not stated in the licence data
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	0.9956
Evidence Level	L4
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, atropine is a non-selective muscarinic acetylcholine receptor antagonist, and its effect on migraine would therefore have to come from blocking cholinergic signalling.

The literature gives a plausible but indirect link:

Meningeal mast cell-mediated cholinergic modulation of neurogenic inflammation in a rat migraine model (PMID 36485173).
Parasympathetic (sphenopalatine ganglion) stimulation causing dural plasma protein extravasation in rats (PMID 9344563).
Autonomic involvement in chronic paroxysmal hemicrania, where systemic atropine reduced attack-related sweating, tearing and nasal secretion (PMID 2943405).

All of this is preclinical or physiological. No study tests atropine as a migraine treatment in humans. Several retrieved papers are off-topic or about adverse events (topiramate, botulinum toxin, a perioperative case report, ergot pharmacology) and add no support.

A second predicted indication, migraine with brainstem aura (score 0.9942, evidence level L5), rests on a single mouse study (PMID 31945385). That study shows cholinergic activation inhibits cortical spreading depression, which, if anything, argues against an antagonist such as atropine. It is not recommended for pursuit.

Clinical Trial Evidence

Currently no related clinical trials are registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2943405	1986	Clinical physiological study	Cephalalgia	In 4 patients with chronic paroxysmal hemicrania, systemic atropine markedly reduced attack-related sweating, tearing and nasal secretion
36485173	2024	Preclinical mechanistic study	Eur J Neurosci	Meningeal mast cell-mediated cholinergic modulation of neurogenic inflammation in a rat migraine model
9344563	1997	Preclinical (rat)	Exp Neurol	Parasympathetic sphenopalatine ganglion stimulation induced plasma protein extravasation in dura mater
8930196	1996	Preclinical (rodent/guinea pig)	J Pharmacol Exp Ther	Central cholinergic system contributes to sumatriptan-induced antinociception
17186568	2007	Review	J Appl Toxicol	Pharmacology of anisodamine, an atropine-like anticholinergic; not migraine-specific
31945385	2020	Preclinical (mouse)	Neuropharmacology	Cholinergic activation inhibits cortical spreading depression via muscarinic receptors (relevant to the aura indication only)

India Market Information

Approved indication text is not provided in the licence records. Twenty valid single-ingredient registrations are on file; the main ones are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
8345	Atronex 0.6mg Injection	Vial of 1 ml injection	Not stated
138128	Malano 0.6mg Injection	Vial of 1 ml injection	Not stated
1268	Atropin Injection	Vial of 1 ml injection	Not stated
181670	Pino Cort Eye Drop	Packet of 5 ml eye drop	Not stated
5858	Atropin Infusion	Bottle of 100 ml infusion	Not stated

Safety Considerations

Drug Interactions: 380 interactions were recorded. Examples at moderate level include botulinum toxin type A, fentanyl, chlorpheniramine, acebutolol, codeine, tramadol, amitriptyline, amantadine, galantamine, loperamide, hyoscyamine and ethanol. Acetaminophen and hydrochlorothiazide are listed as minor.
Expected class effects: Peripheral anticholinergic effects (dry mouth, blurred vision, tachycardia, urinary retention, cognitive effects) are a concern for chronic migraine prophylaxis. This comes from general pharmacology, not from label data compiled here.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high (0.9956), but the supporting evidence is limited to preclinical and indirect studies, with no registered trials and no human data on atropine for migraine. The anticholinergic adverse-effect profile and the large interaction burden further limit feasibility for chronic use.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian licences (currently a blocking gap for safety screening)
Detailed mechanism of action data
Approved indication text for the existing licences
Preclinical or early human proof-of-concept data for atropine in migraine
A feasibility assessment of route and dose (e.g. non-systemic delivery) to limit anticholinergic adverse effects
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.